β-adrenergic-blocking drugs and melanoma: current state of the art

References

• McLoone J, Watts K, Menzies S, Meiser B, Butow P, Kasparian N. When the risks are high: psychological adjustment among melanoma survivors at high risk of developing new primary disease. Qual. Health Res. 22(8), 1102–1113 (2012).
   PubMed Web of Science ®Google Scholar
• Leng Y, Wainwright NW, Hayat S et al. The association between social stress and global cognitive function in a population-based study: the European Prospective Investigation into Cancer (EPIC) – Norfolk study. Psychol. Med. 12, 1–12 (2012).
   Google Scholar
• Al-Wadei HA, Al-Wadei MH, Schuller HM. Prevention of pancreatic cancer by the β-blocker propranolol. Anticancer Drugs 20(6), 477–482 (2009).
   PubMed Web of Science ®Google Scholar
• Sanzo M, Colucci R, Arunachalam M, Berti S, Moretti S. Stress as a possible mechanism in melanoma progression. Dermatol. Res. Pract. 2010, 483493 (2010).
   Google Scholar
• Fitzgerald PJ. Is norepinephrine an etiological factor in some types of cancer? Int. J. Cancer 124(2), 257–263 (2009).
   PubMed Web of Science ®Google Scholar
• Huang XY, Wang HC, Yuan Z, Huang J, Zheng Q. Norepinephrine stimulates pancreatic cancer cell proliferation, migration and invasion via β-adrenergic receptor-dependent activation of P38/MAPK pathway. Hepatogastroenterology 59(115), 889–893 (2012).
   PubMedGoogle Scholar
• Cole SW, Sood AK. Molecular pathways: β-adrenergic signaling in cancer. Clin. Cancer Res. 18(5), 1201–1206 (2012).
   PubMed Web of Science ®Google Scholar
• Liao X, Che X, Zhao W, Zhang D, Bi T, Wang G. The β-adrenoceptor antagonist, propranolol, induces human gastric cancer cell apoptosis and cell cycle arrest via inhibiting nuclear factor κB signaling. Oncol. Rep. 24(6), 1669–1676 (2010).
   PubMed Web of Science ®Google Scholar
• Perron L, Bairati I, Harel F, Meyer F. Antihypertensive drug use and the risk of prostate cancer (Canada). Cancer Causes Control 15(6), 535–541 (2004).
   PubMed Web of Science ®Google Scholar
• Fidjerald PJ. β blockers, norepinephrine, and cancer: an epidemiological viewpoint. Clin. Epidemiol. 4, 151–156 (2012).
   Google Scholar
• Thaker PH, Han LY, Kamat AA et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat. Med. 12(8), 939–944 (2006).
   PubMed Web of Science ®Google Scholar
• Diaz ES, Karlan BY, Li AJ. Impact of β blockers on epithelial ovarian cancer survival. Gynecol. Oncol. doi:10.1016/j.ygyno.2012.07.102 (2012) (Epub ahead of print).
   Google Scholar
• Lands AM, Arnold A, McAuliff JP, Luduena FP, Brown TG Jr. Differentiation of receptor systems activated by sympathomimetic amines. Nature 214(5088), 597–598 (1967).
   PubMed Web of Science ®Google Scholar
• Ahlquist RP. A study of adrenotropic receptors. Am. J. Physiol. 153, 586–600 (1948).
   PubMed Web of Science ®Google Scholar
• Black JW, Stephenson JS. Pharmacology of a new adrenergic β-receptor-blocking compound (nethalide). Lancet 2(7251), 311–314 (1962).
   PubMed Web of Science ®Google Scholar
• Baker JG. The selectivity of β-adrenoceptor antagonists at the human β1, β2 and β3 adrenoceptors. Br. J. Pharmacol. 144(3), 317–322 (2005).
   PubMed Web of Science ®Google Scholar
• Cruickshank JM, Prichard BNC. Chapters 2–6. In: β-Blockers in Clinical Practice (2nd Edition). Cruickshank JM, Prichard BNC (Eds). Churchill Livingstone, Edinburgh, Scotland, UK (1994).
   Google Scholar
• Brodde OE. The functional importance of β 1 and β 2 adrenoceptors in the human heart. Am. J. Cardiol. 62(5), 24C–29C (1988).
   PubMed Web of Science ®Google Scholar
• Man In’t Veld AJ, Van der Meiracker AH, Schalekamp MA. Do β-blockers really increase peripheral vascular resistance? Review of the literature and new observatuons under basal conditions. Am. J. Hypertens. 1, 91–96 (1988).
   PubMed Web of Science ®Google Scholar
• Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol. 11(7), 627–636 (2010).
   PubMed Web of Science ®Google Scholar
• Bangalore S, Kumar S, Kjeldsen SE et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol. 12(1), 65–82 (2011).
   PubMed Web of Science ®Google Scholar
• Barron TI, Sharp L, Visvanathan K. β-adrenergic blocking drugs in breast cancer: a perspective review. Ther. Adv. Med. Oncol. 4(3), 113–125 (2012).
   PubMed Web of Science ®Google Scholar
• Powe DG, Voss MJ, Zänker KS et al. β-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 1(7), 628–638 (2010).
   PubMed Web of Science ®Google Scholar
• Ganz PA, Habel LA, Weltzien EK, Caan BJ, Cole SW. Examining the influence of β blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort. Breast Cancer Res. Treat. 129(2), 549–556 (2011).
   PubMed Web of Science ®Google Scholar
• Melhem-Bertrandt A, Chavez-Macgregor M, Lei X et al. β-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J. Clin. Oncol. 29(19), 2645–2652 (2011).
   PubMed Web of Science ®Google Scholar
• Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K. β blockers and breast cancer mortality: a population-based study. J. Clin. Oncol. 29(19), 2635–2644 (2011).
   PubMed Web of Science ®Google Scholar
• Shah SM, Carey IM, Owen CG, Harris T, Dewilde S, Cook DG. Does β-adrenoceptor blocker therapy improve cancer survival? Findings from a population-based retrospective cohort study. Br. J. Clin. Pharmacol. 72(1), 157–161 (2011).
   PubMed Web of Science ®Google Scholar
• Sendur MA, Aksoy S, Yaman S, Ozdemir NY, Zengin N, Altundag K. Efficacy of angiotensin-receptor blockers on demographic and clinico–pathological characteristics of breast cancer. Breast 21(3), 419–420 (2012).
   PubMed Web of Science ®Google Scholar
• Assimes TL, Elstein E, Langleben A, Suissa S. Long-term use of antihypertensive drugs and risk of cancer. Pharmacoepidemiol. Drug Saf. 17(11), 1039–1049 (2008).
   Google Scholar
• Jansen L, Below J, Chang-Claude J, Brenner H, Hoffmeister M. β-blocker use and colorectal cancer risk: population-based case–control study. Cancer 118(16), 3911–3919 (2012).
   PubMed Web of Science ®Google Scholar
• Glasner A, Avraham R, Rosenne E et al. Improving survival rates in two models of spontaneous postoperative metastasis in mice by combined administration of a β-adrenergic antagonist and a cyclooxygenase-2 inhibitor. J. Immunol. 184(5), 2449–2457 (2010).
   PubMed Web of Science ®Google Scholar
• Yang EV, Kim SJ, Donovan EL et al. Norepinephrine upregulates VEGF, IL-8, and IL-6 expression in human melanoma tumor cell lines: implications for stress-related enhancement of tumor progression. Brain Behav. Immun. 23(2), 267–275 (2009).
   PubMed Web of Science ®Google Scholar
• Sarkar DK, Zhang C, Murugan S et al. Transplantation of β-endorphin neurons into the hypothalamus promotes immune function and restricts the growth and metastasis of mammary carcinoma. Cancer Res. 71(19), 6282–6291 (2011).
   PubMedGoogle Scholar
• Yang EV, Donovan EL, Benson DM, Glaser R. VEGF is differentially regulated in multiple myeloma-derived cell lines by norepinephrine. Brain Behav. Immun. 22(3), 318–323 (2008).
   PubMed Web of Science ®Google Scholar
• Yang EV, Sood AK, Chen M et al. Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res. 66(21), 10357–10364 (2006).
   PubMed Web of Science ®Google Scholar
• Shahzad MM, Arevalo JM, Armaiz-Pena GN et al. Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis. J. Biol. Chem. 285(46), 35462–35470 (2010).
   PubMedGoogle Scholar
• Forsea AM, Del Marmol V, de Vries E, Bailey EE, Geller AC. Melanoma incidence and mortality in Europe: new estimates, persistent disparities. Br. J. Dermatol. doi:10.1111/j.1365-2133.2012.11125.x (2012) (Epub ahead of print).
   Google Scholar
• De Giorgi V, Grazzini M, Gandini S et al. Treatment with β-blockers and reduced disease progression in patients with thick melanoma. Arch. Intern. Med. 171(8), 779–781 (2011).
   PubMed Web of Science ®Google Scholar
• Lemeshow S, Sørensen HT, Phillips G et al. β-blockers and survival among Danish patients with malignant melanoma: a population-based cohort study. Cancer Epidemiol. Biomarkers Prev. 20(10), 2273–2279 (2011).
   PubMed Web of Science ®Google Scholar
• Lens M. Do β-blockers slow down melanoma progression? Arch. Intern. Med. 171(18), 1686–1687; author reply 1687 (2011).
   Google Scholar